

# Einat Even-Sapir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9607405/publications.pdf>

Version: 2024-02-01

50  
papers

3,247  
citations

304368

22  
h-index

197535

49  
g-index

57  
all docs

57  
docs citations

57  
times ranked

3030  
citing authors

#	ARTICLE	IF	CITATIONS
1	The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. <i>Journal of Nuclear Medicine</i> , 2006, 47, 287-97.	2.8	577
2	SNM Practice Guideline for Sodium <sup>18</sup> F-Fluoride PET/CT Bone Scans 1.0. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1813-1820.	2.8	327
3	Detection of Recurrence in Patients with Rectal Cancer: PET/CT after Abdominoperineal or Anterior Resection. <i>Radiology</i> , 2004, 232, 815-822.	3.6	247
4	Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. <i>Journal of Nuclear Medicine</i> , 2004, 45, 272-8.	2.8	247
5	Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1356-67.	2.8	241
6	18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed Tomography. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 462-469.	2.5	174
7	Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1413-20.	2.8	152
8	Head-to-Head Comparison of <sup>68</sup> Ga-PSMA-11 with <sup>18</sup> F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. <i>Journal of Nuclear Medicine</i> , 2020, 61, 527-532.	2.8	142
9	Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1854-1863.	3.3	104
10	The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 541-552.	3.3	92
11	Hybrid Imaging (SPECT/CT and PET/CT)â€”Improving the Diagnostic Accuracy of Functional/Metabolic and Anatomic Imaging. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 264-275.	2.5	85
12	<sup>68</sup> Ga-Labeled Prostate-Specific Membrane Antigen Is a Novel PET/CT Tracer for Imaging of Hepatocellular Carcinoma: A Prospective Pilot Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 185-191.	2.8	79
13	SPECT/multislice low-dose CT: a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for bone scintigraphy. <i>Journal of Nuclear Medicine</i> , 2007, 48, 319-24.	2.8	77
14	Back Pain in Adolescents. <i>Journal of Pediatric Orthopaedics</i> , 2007, 27, 90-93.	0.6	75
15	Clinical applications of gamma-detection probes â€” radioguided surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, S26-S35.	2.2	63
16	Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 743-750.	3.3	63
17	Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin's Disease. <i>Radiologic Clinics of North America</i> , 2007, 45, 697-709.	0.9	61
18	FDG PET Parkinsonâ€™s disease-related pattern as a biomarker for clinical trials in early stage disease. <i>NeuroImage: Clinical</i> , 2018, 20, 572-579.	1.4	60

#	ARTICLE	IF	CITATIONS
19	Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, S65-S81.	3.3	55
20	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3540-3549.	3.3	33
21	[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 953-962.	3.3	27
22	DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers. <i>PLoS ONE</i> , 2017, 12, e0175424.	1.1	27
23	PET/CT in Malignant Bone Disease. <i>Seminars in Musculoskeletal Radiology</i> , 2007, 11, 312-321.	0.4	22
24	[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?. <i>EJNMMI Research</i> , 2019, 9, 84.	1.1	21
25	Personalized radiation dosimetry for PRRT – how many scans are really required?. <i>EJNMMI Physics</i> , 2020, 7, 26.	1.3	21
26	18F-Fluoride PET/Computed Tomography Imaging. <i>PET Clinics</i> , 2014, 9, 277-285.	1.5	18
27	The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. <i>EJNMMI Research</i> , 2021, 11, 3.	1.1	16
28	A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1338-1344.	3.3	15
29	Staging 68Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2077-2085.	3.3	12
30	99mTc-MDP bone scintigraphy of the hand: comparing the use of novel cadmium zinc telluride (CZT) and routine NaI(Tl) detectors. <i>EJNMMI Research</i> , 2015, 5, 63.	1.1	11
31	68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 574.e19-574.e24.	0.8	11
32	Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. <i>Israel Medical Association Journal</i> , 2019, 21, 100-104.	0.1	10
33	Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2447-2449.	3.3	9
34	[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study. <i>Journal of Integrative Neuroscience</i> , 2020, 19, 489.	0.8	8
35	Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes. <i>Clinical Breast Cancer</i> , 2016, 16, 389-395.	1.1	7
36	Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 910-916.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Kidney allografts and remaining contralateral donor kidneys before and after transplantation: assessment by quantitative (99m)Tc-DMSA SPECT. <i>Journal of Nuclear Medicine</i> , 2002, 43, 584-8.	2.8	7
38	Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin's Disease. <i>PET Clinics</i> , 2006, 1, 251-263.	1.5	6
39	Imaging the Normal and Abnormal Anatomy of the Female Pelvis Using 18F FDG-PET/CT, Including Pitfalls and Artifacts. <i>PET Clinics</i> , 2010, 5, 425-434.	1.5	5
40	Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?. <i>Cancers</i> , 2022, 14, 750.	1.7	5
41	Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma. <i>Journal of Nuclear Medicine</i> , 2002, 43, 603-9.	2.8	5
42	PET in women with high risk for breast or ovarian cancer. <i>Lancet Oncology</i> , The, 2010, 11, 899-905.	5.1	4
43	Breast Imaging Utilizing Dedicated Gamma Camera and 99mTc-MIBI: Experience at the Tel Aviv Medical Center and Review of the Literature Breast Imaging. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 286-293.	2.5	4
44	68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	3
45	SPECT versus Planar Scintigraphy as a Clinical Aid in Evaluation of the Elderly with Knee Pain. <i>ISRN Orthopedics</i> , 2013, 2013, 1-11.	0.7	2
46	68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy. <i>Diagnostics</i> , 2021, 11, 277.	1.3	2
47	Node positive breast cancer: Concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy. <i>Surgical Oncology</i> , 2019, 30, 1-5.	0.8	1
48	Coincidence imaging using 2 dual-head gamma-camera systems, with and without attenuation correction. <i>Journal of Nuclear Medicine Technology</i> , 2004, 32, 190-7.	0.4	1
49	The Utility of 18F-fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Cutaneous B-Cell Lymphoma. <i>Israel Medical Association Journal</i> , 2019, 21, 580-584.	0.1	1
50	Pet Imaging of Bone Metastases Using Different Tracers. , 2017, , 269-273.		0